公开(公告)号：EP3708650A1

公开(公告)日：2020-09-16

申请号：EP20167102.1

申请日：2015-09-18

Applicant: Japan Science and Technology Agency

Inventor： KAWAOKA, Yoshihiro ,  WATANABE, Tokiko ,  KAWAKAMI, Eiryo ,  WATANABE, Shinji

IPC: C12N5/00 ,  C12N5/10 ,  C12N7/02 ,  C12N15/113

Abstract: The present invention provides cells which have a high ability to propagate influenza virus, are suitable for use in production of an influenza virus for preparing a vaccine, and are able to be cultured in vitro, and a method for producing an influenza virus using the cells. That is, the present invention provides cells for producing an influenza virus in which expression of one or more genes that encode proteins involved in an effect of suppressing influenza virus production in a cell is suppressed and the gene is at least one selected from the group including ACTG1 gene and the like, and a method for producing an influenza virus that includes infecting the cells for producing an influenza virus with an influenza virus and then culturing.

公开(公告)号：EP2905363B1

公开(公告)日：2020-02-19

申请号：EP13844515.0

申请日：2013-09-27

Applicant: Japan Science and Technology Agency

Inventor： DA SILVA LOPES, Tiago Jose ,  KITANO, Hiroaki ,  KAWAOKA, Yoshihiro

IPC: G16B5/00

公开(公告)号：EP2905363A1

公开(公告)日：2015-08-12

申请号：EP13844515.0

申请日：2013-09-27

Applicant: Japan Science and Technology Agency

Inventor： DA SILVA LOPES, Tiago Jose ,  KITANO, Hiroaki ,  KAWAOKA, Yoshihiro

IPC: C40B30/02 ,  G06F17/18 ,  G06F17/30 ,  G06F19/16

CPC classification number: G06N5/04 ,  G06N20/00 ,  G06Q10/10 ,  G16B5/00 ,  G16B35/00 ,  G16C20/50 ,  G16C20/60 ,  G16C20/70

Abstract: According to an aspect of the present invention, similarity centrality measures that are centrality measures of proteins that a protein similarity network includes are calculated, interaction centrality measures that are centrality measures of the proteins that the protein-protein interaction network includes are calculated, a rejection score that represents probability of a compound to be validated to be classified as a rejected drug is calculated using classifiers that use, as training data, the approval attributes of the respective drugs, the sum and average of the similarity centrality measures per target for each drug, and the sum and average of the interaction centrality measures per target for each drug, and the rejection score is output.

Abstract translation: 根据本发明的一个方面，计算蛋白质相似性网络所包含的蛋白质的中心性度量的相似性中心度量度，作为蛋白质 - 蛋白质相互作用网络所包含的蛋白质的中心性度量的交互中心度量被计算， 使用分类器来计算代表化合物被鉴定为被拒绝药物的概率的分数，该分类器使用各种药物的批准属性作为培训数据，每种药物的每个靶标的相似性中心度量的总和和平均值 ，每个药物每个目标的互动中心度量的总和和平均值，输出排除分数。